Gliclazide is an oral hypoglycemic and is classified as a sulfonylurea. It is marketed as Glyloc and Reclide in India. The modified-release formulations are also marketed now. Its classification has been ambiguous, as literature uses it as both a first-generation and second-generation sulfonylurea. Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset or adult type. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate.